Epidiolex® for Anxiety in Pediatric Epilepsy

Inclusion Criteria

• •1. Established diagnosis of epilepsy, characterized by focal or generalized seizures. All participants will have active epilepsy that requires treatment with anticonvulsant medication.
• •2. No episodes of seizure clusters of status epilepticus within 30 days prior to entry into the study.
• •3. Established symptoms of anxiety with functional impairment.
• •4. Baseline behavioral criteria for inclusion will include subscale scores for anxiety above the norm for age and gender inth e 60 days prior to the study on one of the following:
• •5. Male or female participants equal to or above age 6 and below age 18 at the start of the study. No exclusion will be made on the basis of gender or minority status.
• •6. Ability to administer medicine orally
• •7. Previous subjects who failed at any point to meet continuation criteria and withdrew early may be considered for re-enrollment by the PI on a case-by-case basis.
• •8. Participant or legal caregiver capable of providing informed consent and fully capable of monitoring the subject's disease process and compliance with treatment.
• •9. Participants who are sexually active, must agree to sexual abstinence, or, to use an approved birth control method for the full duration of study participation.
• •10. No active use of CBD products within the 14 days prior to screening visit and commitment to only use study product for the duration of the study.